Synulox powder for oral suspension for cats and dogs 15 ml
Treatment of skin disease, soft tissue infections, dental infections, urinary tract infections, respiratory disease and enteritis in cats and dogs
SYNULOX PALATABLE DROPS, Powder for Oral Suspension
SYNULOXQUALITATIVE AND QUANTITATIVE COMPOSITION
mg/ml when Active ingredients: mg per bottle reconstituted
Amoxicillin 648.0 40.0 (as Amoxicillin Trihydrate) 743.9 45.92
Clavulanic acid 154.3 10.0 (as Potassium Clavulanate) 183.6 11.9
For the full list of all other excipients see section 6.1.
SYNULOX PHARMACEUTICAL FORM
Powder for oral suspension. An off-white coloured powder for reconstitution.
SYNULOX CLINICAL PARTICULARS
Cats and dogs.
Indications for use, specifying the target species
The product is indicated for the treatment of a wide range of diseases of cats and dogs including: skin diseases (including deep and superficial pyodermas); urinary tract infections; respiratory diseases (involving upper and lower respiratory tract); enteritis; soft tissue infections (abscesses and anal sacculitis); dental infections (e.g. gingivitis).
The product is effective against Klebsiella infections found in veterinary practice, but it is not indicated for cases involving Pseudomonas species.
The product should not be given to rabbits, guinea pigs, hamsters or gerbils. Caution is advised in their use in any other very small herbivores.
Special warnings for each target species
Special precautions for use
Special precautions for use in animals
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.
Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
Handle this product with great care to avoid exposure, taking all recommended precautions.
If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.
Wash hands after use.
Adverse reactions (frequency and seriousness)
Use during pregnancy, lactation or lay
The product can be safely used in pregnant and lactating animals.
Interaction with other medicinal products and other forms of interaction
It is not advisable to use bacterial and bacteriostatic antibiotics in combination.
Amounts to be administered and administration route
Reconstitution: Add 15 ml water. Shake the bottle before use.
Administration: by the oral route.
Dosage rate: 12.5 mg/kg bodyweight (i.e. 0.25 ml/kg). For the accurate dosing of particularly small patients it is valuable to note that one drop from the pipette provided contains 2.3 mg clavulanate-potentiated amoxicillin. Therefore 5-6 drops/kg twice daily are recommended as a guide.
Dosage frequency: Dogs and cats should be dosed at the rate of 0.25 ml of reconstituted product per kg bodyweight twice daily.
For the majority of infections, including those of the skin, urinary tract and gastrointestinal tract, the above dosage regime is effective. Refractory cases however, particularly those of the respiratory tract, have shown improved cure rates by doubling the dose to 25 mg/kg bodyweight, twice daily (i.e. 0.5 ml of reconstituted product twice daily).
Duration of therapy: Routine cases involving all indications: the majority of these cases respond to between 5 and 7 days therapy.
Chronic or refractory cases: In these cases, where there is considerable tissue damage, a longer course of therapy may be required in that it allows sufficient time for damaged tissue to repair. Based on clinical trials, the following durations are suggested as guidelines:
Chronic skin disease 10 - 20 days Chronic cystitis 10 - 28 days Respiratory disease 8 - 10 days
Overdose (Symptoms, emergency procedures, antidotes), if necessary
The product is of low order toxicity to the target species. No adverse side effects are to be expected from accidental overdose.
SYNULOX PHARMACOLOGICAL PROPERTIES
The product has a notably broad spectrum of bactericidal activity against bacteria commonly found in cats and dogs.
In vitro the product is active against a wide range of clinically important aerobic and anaerobic bacteria including:
Staphylococci (including ß-lactamase producing strains)
Bacteroides spp. (including ß-lactamase producing strains)
Escherichia coli (including most ß-lactamase producing strains)
Salmonellae (including ß-lactamase producing strains)
Resistance to many antibiotics is caused by ß-lactamase enzymes which destroy the antibiotic before it can act on the bacteria themselves. The clavulanate in the product counteracts this defence mechanism by inactivating the ß-lactamases, thus rendering the organisms sensitive to amoxicillin’s rapid bactericidal effect, at concentrations readily attainable in the body.
ATCvet Code: QJ01CR02
SYNULOX PHARMACEUTICAL PARTICULARS
List of excipients
Saccharin Sodium Anhydrous
Silica Colloidal Anhydrous
Silicon Dioxide (Silica Gel)
Strawberry Dry Flavour
Peach Dry Flavour
Lemon Dry Flavour
Shelf life of the veterinary medicinal product as packaged for sale: 18 months.
Shelf life after dilution or reconstitution according to directions: 7 days.
Special precautions for storage
Do not store above 25°C. The reconstituted product should be stored at 2-8°C.
Any reconstituted product remaining 7 days after preparation should be discarded.
Nature and composition of immediate packaging
The product is supplied in glass bottles (containing 15ml of product following reconstitution). A dropper with graduations of 0.25 ml, up to 1 ml, is included in each pack to ensure accurate, convenient dosing.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
MARKETING AUTHORISATION HOLDER
Zoetis UK Limited
5th Floor, 6 St. Andrew Street